These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33635844)

  • 1. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
    Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G
    AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
    Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
    J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
    Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness, Weight Changes, and Metabolic Outcomes on Switch to Generic Dolutegravir/Lamivudine Among People with HIV in Western India: An Observational Study.
    Pujari S; Gaikwad S; Panchawagh S; Chitalikar A; Joshi K; Rohekar C; Dabhade D; Bele V
    AIDS Res Hum Retroviruses; 2024 Apr; 40(4):204-215. PubMed ID: 38063004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
    Focà E; Calcagno A; Calza S; Renzetti S; Chiesa A; Siano M; De Socio G; Piconi S; Orofino G; Madeddu G; Cattelan AM; Nozza S; Ferrara M; Milic J; Celesia BM; Castelli F; Guaraldi G
    PLoS One; 2021; 16(10):e0258533. PubMed ID: 34644336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.
    Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J
    HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
    Maphosa T; Dunga S; Makonokaya L; Woelk G; Maida A; Wang A; Ahimbisibwe A; Chamanga RK; Zimba SB; Kayira D; Machekano R
    BMC Public Health; 2024 May; 24(1):1321. PubMed ID: 38755632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.
    Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL
    AIDS; 2020 Jan; 34(1):109-114. PubMed ID: 31567162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
    Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
    Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight Gain Among Treatment-Naïve Persons With HIV Receiving Dolutegravir in Kenya.
    Bourgi K; Ofner S; Musick B; Griffith B; Diero L; Wools-Kaloustian K; Yiannoutsos CT; Gupta SK
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):490-496. PubMed ID: 36126175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort.
    Teira R; Diaz-Cuervo H; Aragão F; Castaño M; Romero A; Roca B; Montero M; Galindo MJ; Muñoz-Sánchez MJ; Espinosa N; Peraire J; Martínez E; de la Fuente B; Domingo P; Deig E; Merino MD; Geijo P; Estrada V; Sepúlveda MA; García J; Berenguer J; Currán A
    Infect Dis Ther; 2022 Jun; 11(3):1177-1192. PubMed ID: 35399147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.
    Lahiri CD; Mehta CC; Sykes C; Weiser SD; Palella F; Lake JE; Mellors JW; Gustafson D; French AL; Adimora AA; Konkle-Parker D; Sharma A; Bolivar H; Kassaye SG; Rubin LH; Alvarez JA; Golub ET; Ofotokun I; Sheth AN
    AIDS Res Hum Retroviruses; 2023 Dec; 39(12):644-651. PubMed ID: 37140468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
    Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
    Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
    Nakatudde I; Katana E; Agnes Odongpiny EL; Nalugga EA; Castelnuovo B; Fowler MG; Musoke P
    AIDS Res Ther; 2024 Apr; 21(1):23. PubMed ID: 38637785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body weight and blood pressure changes on dolutegravir-, efavirenz- or atazanavir-based antiretroviral therapy in Zimbabwe: a longitudinal study.
    Shamu T; Egger M; Mudzviti T; Chimbetete C; Manasa J; Anderegg N
    J Int AIDS Soc; 2024 Feb; 27(2):e26216. PubMed ID: 38332525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.